💊 Medication
bempedoic acid
An oral non-statin LDL-lowering drug, useful for statin-intolerant patients. Strong evidence it lowers LDL (~20%) and reduces cardiovascular events (CLEAR Outcomes), though the hard-outcome data rest largely on that single trial program; it raises uric acid and gout risk. A proposed anti-Alzheimer's effect is unproven speculation.
4 well-supported · 0 disputed. This shows how settled each sub-question is, not whether bempedoic acid is "good." Direction lives in each claim below.
The 4 claims about bempedoic acid
Each keeps its own verdict — we never average them away.
Does bempedoic acid lower LDL cholesterol, and by how much?
Strong support Yes — consistently ~15-25% LDL-C reduction (≈17-18% on a statin background, ~21-28% as monotherapy/statin-intolerant; ~38% with ezetimibe), proven across the CLEAR phase 3 program and multiple meta-analyses.
Does bempedoic acid raise serum uric acid and increase gout risk?
Strong support Yes — it modestly and reversibly raises serum uric acid (via OAT2/OAT3 inhibition of renal urate excretion) and increases gout incidence roughly 1.5-3 fold, concentrated in those with prior gout or high baseline urate; absolute risk remains low.
Could the cholesterol drug bempedoic acid, by switching on PPAR-alpha, steer the brain away from making Alzheimer's amyloid?
Strong support Independent mouse and mechanistic work consistently shows PPAR-alpha activation — which bempedoic acid does (Cell Metab 2026) — can steer APP away from the amyloid pathway and boost amyloid clearance, and that pathway evidence is what carries the grade. But no study tests bempedoic acid itself in the brain, so this is a mechanism/animal-grade inference about a plausible repurposing, NOT a demonstrated anti-amyloid effect in people.
Does bempedoic acid reduce major adverse cardiovascular events (MACE)?
Strong support Yes — CLEAR Outcomes (the sole large CV outcomes RCT) showed a 13% relative reduction in 4-point MACE in statin-intolerant high-risk patients, confirmed by meta-analyses; driven by MI and revascularization, with no reduction in CV or all-cause death.
Educational only, not medical advice. Hub descriptions are curated for honesty; see the methodology.